Compare Bitwise Crypto Industry Innovators ETF (BITQ) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bitwise Crypto Industry Innovators ETF vs Zoetis Inc — how do they compare? Bitwise Crypto Industry Innovators ETF trades at $22.69, while Zoetis Inc trades at $72.53 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while Bitwise Crypto Industry Innovators ETF pays none, and Bitwise Crypto Industry Innovators ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| BITQ | ZTS | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $30.43 | $156.76 |
52-Week Low | $16.74 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITQ trades at $22.77, up 2.59% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks available fundamental data such as P/E, revenue, or earnings metrics. Recent news highlights institutional interest in crypto ETFs, though BITQ itself is a US stock with no direct crypto operations.
The outlook remains cautious due to bearish technicals and absent financials. Risks include market volatility and competition, while opportunities hinge on future earnings clarity. Investors should await fundamental updates for a clearer investment thesis.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bitwise Crypto Industry Innovators ETF
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
